Uncategorized

As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk

Published

on

When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version